Medicare AdvantageApril 1, 2022
Clinical Criteria updates
Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other members of your practice and office staff.
Please note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
Effective date |
Document number |
Clinical Criteria Title |
New or revised |
04/08/2022 |
*ING-CC-0205 |
Fyarro (sirolimus albumin bound) |
New |
04/08/2022 |
*ING-CC-0206 |
Besremi (ropeginterferon alfa-2b-njft) |
New |
04/08/2022 |
*ING-CC-0207 |
Vyvgart (efgartigimod alfa-fcab) |
New |
04/08/2022 |
*ING-CC-0208 |
Adbry (tralokinumab) |
New |
04/08/2022 |
*ING-CC-0209 |
Leqvio (inclisiran) |
New |
04/08/2022 |
ING-CC-0124 |
Keytruda (pembrolizumab) |
Revised |
04/08/2022 |
ING-CC-0079 |
Strensiq (Asfotase Alfa) |
Revised |
04/08/2022 |
ING-CC-0015 |
Infertility and HCG Agents |
Revised |
04/08/2022 |
ING-CC-0102 |
Gonadotropin releasing hormone (GNRH) Analogs for Oncologic Indications |
Revised |
04/08/2022 |
ING-CC-0168 |
Tecartus (brexucabtagene autoleucel) |
Revised |
04/08/2022 |
ING-CC-0029 |
Dupixent (dupilumab) |
Revised |
04/08/2022 |
*ING-CC-0004 |
Repository Corticotropin Injection |
Revised |
04/08/2022 |
ING-CC-0072 |
Selective Vascular Endothelial Growth Factor (VEGF) Antagonists |
Revised |
PUBLICATIONS: April 2022 Anthem Provider News - Wisconsin
To view this article online:
Visit https://providernews.anthem.com/wisconsin/articles/clinical-criteria-updates-44-10279
Or scan this QR code with your phone